Lead site Memorial Sloan Kettering Cancer Center (MSKCC)
Timing of milestone in-line with mid-2024 guidance
Data from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate
July 08, 2024 -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the 1st patient has been dosed at MSKCC in its U.S. NEXICART-2 tria